



Plan your time at Discovery on Target. Register for the Premium Package.

Choose 2 Conferences/Training Seminar(s) and 2 Short Courses* and 1 Symposium*

| PROGRAM/MODULE NAME | S1: Strategies for Targeting Kinases | S2: Covalent Chemistries and Induced Proximity | S3: Emerging Immune Modulation Strategies | S4: Synthetic Biology for Drug Discovery and Therapy | SC1: Protein Degraders: A Focus on PROTACs from an ADME-Tox Perspective | SC2: Fragment-Based Drug Design: Advancing Tools and Technologies | SC3: DNA-Encoded Libraries | SC4: Best Practices for Targeting GPCRs, Ion Channels, and Transporters with Monoclonal Antibodies | SC5: Developing Physiologically Relevant 3D Models | SC6: Protein Degraders: A Focus on PROTACs from a Beyond Rule of Five Space Perspective | SC7: Chemical Biology for Covalent Discovery, Phenotypic Screening, and Target Deconvolution | SC8: Biophysical Approaches for GPCRs | SC9: Fundamentals of Generative AI for Drug Discovery |
|---|--------------------------------------|--|---|--|---|---|----------------------------|--|--|---|--|---------------------------------------|---|
| S1: Strategies for Targeting Kinases | | | | | ✓ | | | | ✓ | ✓ | | | |
| S2: Covalent Chemistries and Induced Proximity | | | | | ✓ | | | | | | ✓ | | |
| S3: Emerging Immune Modulation Strategies | | | | | ✓ | | | | | | ✓ | | |
| S4: Synthetic Biology for Drug Discovery and Therapy | | | | | ✓ | | | | | | | | ✓ |
| C1A: Degraders and Molecular Glues – Part 1 | ✓ | ✓ | | | ✓ | | | | | ✓ | | | |
| C2A: Lead Generation Strategies | ✓ | ✓ | | | | ✓ | ✓ | | | | ✓ | ✓ | |
| C3A: Small Molecules for Cancer Targets | | | ✓ | | | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | |
| C4A: Antibodies Against Membrane Protein Targets | | | | | | | | ✓ | | | | ✓ | |
| C5A: Small Molecules Targeting RNA | | | | ✓ | ✓ | | | | | | ✓ | | |
| C6A: AI/ML-Enabled Drug Discovery – Part 1 | | | | ✓ | ✓ | | | | ✓ | | | | ✓ |
| C7A: Physiologically Relevant Translational Models | | | | ✓ | | | | | | | | | |
| C1B: Degraders and Molecular Glues – Part 2 | ✓ | ✓ | | | ✓ | | | | | ✓ | | | |
| C2B: Target Identification Strategies | ✓ | | | | | | | | ✓ | | ✓ | | |
| C3B: GPCR-Based Drug Discovery | | | | ✓ | | | | ✓ | | | | ✓ | |
| C4B: Cancer Antibodies | | | ✓ | | | | | ✓ | | | | | |
| C5B: Targeting Transcription Factors | | | ✓ | | ✓ | | | | | | ✓ | | |
| C6B: AI/ML-Enabled Drug Discovery – Part 2 | | | | ✓ | | | | | ✓ | | | | ✓ |
| TS8A: IN-PERSON ONLY GPCR Pharmacodynamics: Kinetics, Allosterism, and Biased Agonism in Pharma Discovery | | ✓ | | ✓ | | | | ✓ | | | | ✓ | |
| TS7B: IN-PERSON ONLY Drug Exposure at the Target: The Role of ADME and Pharmacokinetics | ✓ | | | | ✓ | | | | | | ✓ | | |

*Separate registration required.